Modern therapy of psoriasis from the point of view of systemic inflammation: experience of using the drug Efleira


DOI: https://dx.doi.org/10.18565/pharmateca.2021.8.34-41

N.A. Merzlikina (1), E.V. Svechnikova (1, 2), S.E. Zhufina (1)

1) Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia; 2) Novosibirsk State Medical University, Novosibirsk, Russia
The article discusses clinical cases of patients with moderate and severe plaque psoriasis, psoriasis with involvement of sensitive area such as the scalp and nails, as well as with the presence of psoriatic arthritis. The purpose of this article is to evaluate the effectiveness of therapy for moderate-to-severe plaque psoriasis, psoriasis with involvement of sensitive area, as well as psoriasis with concomitant psoriatic arthritis with the new original IL-17 inhibitor netakimab (Efleira®). The experience obtained and presented in this review on the example of 4 clinical cases shows good results of therapy with the new original IL-17 inhibitor netakimab (Efleira®) not only in terms of assessing the skin status, but also in terms of a beneficial effect on the processes of systemic inflammation in psoriasis.

About the Autors


Corresponding author: Natalya A. Merzlikina, Dermatovenerologist, Department of Dermatovenereology and Cosmetology, Polyclinic № 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia; natalya.pryahina90@mail.ru
Address: 26/28 Sivtsev Vrazhek lane, Moscow 119002, Russian Federation


Similar Articles


Бионика Медиа